U.S. Markets closed

IntelliPharmaCeutics International Inc. (IPCI)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
0.95-0.02 (-2.06%)
At close: 4:00PM EDT
People also watch
CPRXAPRIIDRAACRXBLRX
Full screen
Previous Close0.97
Open0.93
Bid0.75 x 2000
Ask0.94 x 2000
Day's Range0.90 - 0.98
52 Week Range0.81 - 3.35
Volume217,037
Avg. Volume331,866
Market Cap29.33M
BetaN/A
PE Ratio (TTM)-2.84
EPS (TTM)N/A
Earnings DateN/A
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Trade prices are not sourced from all markets
  • Newsfile24 days ago

    IIROC Trade Resumption - Intellipharmaceutics International Inc.

    Toronto, Ontario--(Newsfile Corp. - July 27, 2017) - Trading resumes in: Company: Intellipharmaceutics International Inc. TSX Symbol: IPCI (All issues) ...

  • Reuters25 days ago

    FDA panel votes against approving Intellipharma's opioid painkiller

    A panel of independent advisers to the U.S. Food and Drug Administration concluded on Wednesday that there is not enough evidence to support the approval of Intellipharmaceutics International Inc's long-acting opioid painkiller. Toronto-based Intellipharma's painkiller has been developed as a unique abuse-deterrent version of Purdue Pharma's oft-abused blockbuster OxyContin, which already has tamper-resistant properties. In a preliminary review on Monday, FDA scientists raised concerns that Intellipharma had not provided adequate data on the abuse potential of the drug as part of its U.S. marketing application.

  • Reuters27 days ago

    Abuse-liability data on Intelli's opioid drug missing - FDA staff

    U.S. Food and Drug Administration scientists on Monday raised concerns that Intellipharmaceutics International Inc failed to provide data from studies testing the abuse potential of its long-acting opioid painkiller. Canada-based Intellipharma's product, Rexista, has been developed as a unique abuse-deterrent version of Purdue Pharma's OxyContin, which already has tamper-resistance properties. In a preliminary review posted ahead of a meeting of independent advisers on Wednesday, FDA scientists said that abuse-liability data had not been submitted as part of Rexista's marketing application.